IRC011, a new synthetic chelator with selective interaction with catabolic red blood cell iron: Evaluation in hypertransfused rats with hepatocellular and reticuloendothelial radioiron probes and in iron-loaded rat heart cells in culture

Blood

Volumn 90, Issue 10, 1997, Pages 4180-4187

  Rivkin, Gurion ^b   Link, Gabriela ^b   Simhon, Elliot ^b   Cyjon, Rosa L ^b   Klein, Joseph Y ^b   Hershko, Chaim ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; CHROMIUM 51; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON 59;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD TRANSFUSION; CATABOLISM; CONTROLLED STUDY; FEMALE; HEART MUSCLE CELL; INTRAPERITONEAL DRUG ADMINISTRATION; IRON CHELATION; IRON OVERLOAD; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RETICULOENDOTHELIAL SYSTEM;

EID: 0030733850     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.10.4180     Document Type: Article

References (38)

1. Gabutti V, Piga A: Results of long-term iron chelating therapy. Acta Haematol 95:26, 1996
2. Olivieri NF, Nathan DG, MacMillan JH, Wayne AD, Martin M, McGee A, Koren G, Liu PP, Cohen AR: Survival of medically treated patients with homozygous b thalassemia. N Engl J Med 331:574, 1994
3. al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ: Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 80:592, 1992
4. al-Refaie FN, Wonke B, Hoffbrand AV: Deferiprone-associated myelotoxicity. Eur J Haematol 53:298, 1994
5. Hershko C: Development of oral iron chelator L1. Lancet 341:1088, 1993
6. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B: Results of long-term deferiprone (L1) therapy: A report by the International Study Group on Oral Iron Chelators. Br J Haematol 91:224, 1995
7. Winchell HS, Klein JY, Simhon ED, Cyjon RL, Klein O, Zaklad H: Compounds with chelation affinity and selectivity for first transition series elements: Use in medical therapy and diagnosis. Patent Cooperative Treaty (PCT) document 96/10785. December 27, 1996
8. Hershko C: Biologic models for studying iron chelating drugs. Clin Haematol 2:293, 1989
9. Bjorklid E, Helgeland L: Sex difference in the ferritin content of rat liver. Biochim Biophys Acta 221:583, 1970
10. Hershko C, Grady RW, Link G: Phenolic ethylenediamine derivatives: A study of orally effective iron chelators. J Lab Clin Med 103:337, 1984
11. Hershko C, Cook JD, Finch CA: Storage iron kinetics III: Study of desferrioxamine action by selective radioiron labels of RE and parenchymal cells. J Lab Clin Med 81:876, 1973
12. Zevin S. Link G, Grady RW, Hider RC, Peter HH, Hershko C: Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: Studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores. Blood 79:248, 1992
13. Torrance JD, Bothwell TH: A simple technique for measuring storage iron concentrations in formalinized liver samples. S Afr J Med Sci 33:9, 1968
14. Link G, Pinson A, Hershko C: Heart cells in culture: A model of myocardial iron overload and chelation. J Lab Clin Med 106:147, 1985
15. Hershko C, Link G, Pinson A, Peter HH, Dobbin P, Hider RC: Iron mobilization from myocardial cells by 3-hydroxypridin-4-one chelators: Studies in rat heart cells in culture. Blood 77:2049, 1991
16. Link G, Pinson A, Hershko C: Iron loading of cultured cardiac myocytes modifies sarcolemmal structure and increases lysosomal fragility. J Lab Clin Med 121:127, 1993
17. Link G, Tirosh R, Pinson A, Hershko C: Role of iron in the potentiation of anthracycline cardiotoxicity: Identification of heart cell mitochondria as a major site of iron-anthracycline interaction. J Lab Clin Med 127:272, 1996
18. Hider RC, Choudhury R, Rai BL, Dehkordi LS, Singh S: Design of orally active iron chelators. Acta Haematol 95:6, 1966
19. Dobbin PS, Hider RC, Hall AD, Taylor PD, Sarpong P, Porter JB, Xiao G, Van der Helm D: Synthesis, physicochemical properties, and biological evaluation of substituted 2-alkyl-3-hydroxy-4 (1h)-pyridones: Orally active iron chelators with clinical potential. J Med Chem 20:2448, 1993
20. Hershko C: Iron chelators in medicine. Mol Aspects Med 13:114, 1992
21. Hershko C: Determinants of fecal and urinary iron excretion in desferrioxamine treated rats. Blood 51:415, 1978
22. Hershko C, Weatherall DJ: Iron chelating therapy. CRC Crit Rev Cin Lab Sci 303, 1988
23. Borgna-Pignatti C, Zurlo MG, DeStefano P, DiGregorio F, Di Palma A, Piga A, Melevendi C, Burattini MG, Terzoli S, Masera G: Survival in thalassemia with conventional treatment, in Buckner CD, Gale RP, Lucarelli G (eds): Advances and Controversies in Thalassemia Therapy: Bone Marrow Transplantation and Other Approaches. New York, NY, Liss, 1989, 27
24. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R, Freedman MH, Nathan DG: Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 312:1600, 1985
25. Pootrakul P, Kitcharoen K, Yansukon P, Wasi P, Fucharoen S, Charoenlarp P, Brittenham G, Pippard MJ, Finch CA: The effect of erythroid hyperplasia on iron balance. Blood 71:1124, 1988
26. Hershko C, Rachmilewitz EA: Mechanism of desferrioxamine iron excretion in thalassaemia. Br J Haematol 42:125, 1979.
27. Pippard MJ, Callender ST, Finch CA: Ferrioxamine excretion in iron-loaded man. Blood 60:288, 1982
28. Hershko C, Peto TEA: Non-transferrin plasma iron. Br J Haematol 66:149, 1987
29. al-Refaie FRN, Wickens DG, Wonke B, Kontoghiorghes GJ, Hoffbrand AV: Serum non-transferrin-bound iron in beta-thalassaemia major patients treated with deferoxamine and L1: Br J Haematol 82:431, 1992
30. Gutteridge JMC, Rowley DA, Griffiths E, Halliwell B: Low-molecular-weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci Lond 68:463, 1985
31. Brissot P, Wright TL, Ma WL, Weisiger RA: Efficient clearance of non-transferrin bound iron by rat liver. Implications for hepatic iron loading in iron overload states. J Clin Invest 76:1463, 1985
32. Brissot P, Zaninelli G, Guyader G, Zeind J, Gollan JL: Biliary excretion of non-transferrin bound iron in rats: Pathogenetic importance in iron-overload disorders. Am J Physiol 267:G135, 1994
33. Randell EW, Parkes JG, Olivieri NF, Templeton DM: Uptake of non-transferrin iron by both reductive and non reductive processes is modulated by intracellular iron. J Biol Chem 23:16026, 1994
34. Porter JB, Abeysinghe RD, Marshall L, Hifer RC, Singh S: Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. Blood 88:705, 1996
35. Hershko C: A study of the chelating agent diethylenetriamine pentaacetic acid using selective radioiron probes of R.E. and parenchymal iron stores. J Lab Clin Med 85:913, 1975
36. Hershko C, Grady RW, Cerami A: Mechanism of iron chelation in the hypertransfused rat: Definition of two alternative pathways of iron mobilization. J Lab Clin Med 92:144, 1978
37. Pippard MJ, Jackson MJ, Hoffman K, Petrou M, Modell CB: Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA). Scand J Haematol 36:466, 1986
38. Wonke B, Hoffbrand AV, Aldouri M, Wickens D, Flynn D, Stearns M, Warner P: Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. Arch Dis Child 64:77, 1989